Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Long-Term Investments (2020 - 2023)

Oncology Institute's Long-Term Investments history spans 4 years, with the latest figure at $58.9 million for Q2 2023.

  • For Q2 2023, Long-Term Investments changed N/A year-over-year to $58.9 million; the TTM value through Jun 2023 reached $58.9 million, changed N/A, while the annual FY2022 figure was $58.4 million, N/A changed from the prior year.
  • Long-Term Investments reached $58.9 million in Q2 2023 per TOI's latest filing, roughly flat from $58.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $230.3 million in Q1 2021 to a low of $58.2 million in Q3 2022.
  • Average Long-Term Investments over 4 years is $161.5 million, with a median of $230.0 million recorded in 2021.
  • Peak YoY movement for Long-Term Investments: fell 0.05% in 2021, then plummeted 74.69% in 2022.
  • A 4-year view of Long-Term Investments shows it stood at $230.3 million in 2020, then dropped by 0.1% to $230.0 million in 2021, then tumbled by 74.63% to $58.4 million in 2022, then rose by 1.01% to $58.9 million in 2023.
  • Per Business Quant, the three most recent readings for TOI's Long-Term Investments are $58.9 million (Q2 2023), $58.8 million (Q1 2023), and $58.4 million (Q4 2022).